Investigator-initiated Trials

Celgene Corporation is committed to changing the course of human health through bold pursuits in science. The mission and purpose of the Investigator-Initiated program are to provide support for investigator-initiated research (“IITs”) in disease areas that help advance the medical and scientific knowledge of Celgene compounds.

BMS has decided to modify its COVID-19 ISR application process, changing from a rolling submission process to a time-period specific “Request for Proposal (RFP) process”. The submission period will be open from July 27th through August 15th, 2020.

  • The new process will be limited to COVID-19 concepts only.
  • Due to the alliance between Pfizer and BMS, COVID-19 concepts involving apixaban will continue with the existing review processes outside of this RFP.
  • All non COVID-19 proposals will continue their existing processes.

Click here to review the COVID-19 specific “Areas of Interest”.
For questions and more information, please contact your local BMS Medical Representative.

Celgene may provide grant funding, and/or drug supply depending on the type of research.  Proposals are reviewed by the Celgene Internal Review Committee (IRC) based on scientific merit, research priorities, and available resources.

If you are:

  • from any country interested in proposing an Inflammation and Immunology IIT, or
  • located in the Americas, proposing an IIT in the area of Hematology or Oncology

Please submit your request directly through IMAGE – Celgene’s “IIT Medical Affairs Global Enterprise” System. Submission of a request does not guarantee approval.
 

Submit a request for a Clinical Investigator-initiated Trial

 
If you are a located outside of the Americas and wish to propose a Hematology or Oncology IIT, please contact your local Field Medical Associate or Local Celgene office to discuss your IIT proposal.
 
Celgene logo, IMAGE logo